Base4 and Hitachi High-Tech Collaborate on Developing Novel Nanopore DNA-Sequencing System - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Base4 and Hitachi High-Tech Collaborate on Developing Novel Nanopore DNA-Sequencing System
The core DNA-sequencing technology is based on the concept of passing a single strand of DNA through a nanometer-scale pore and reading out the sequence directly as it does so.


Base4 Innovation Ltd., a Cambridge-based DNA-sequencing company, and Hitachi High-Technologies Corporation, a technology company developing and manufacturing scientific and medical systems, announced that they have entered into an agreement to develop a long read-length, single-molecule, nanopore-based DNA-sequencing system based on Base4’s technology and Hitachi’s state-of-the-art instrumentation.

The core DNA-sequencing technology is based on the concept of passing a single strand of DNA through a nanometer-scale pore and reading out the sequence directly as it does so. A method was developed by Base4 to increase the signal from the single molecule as it passes through the pore by using laser light enhanced by gold structures. Minimal sample preparation is required and the signal can be read from unlabelled DNA.

The system offers easy analysis of genetic material. It will be able to directly read DNA modifications, such as methylation, which is relevant to the genes associated with cancer, as well as achieve long read lengths.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
33%
Breakthrough designations
11%
Protecting the supply chain
39%
Expedited reviews of drug submissions
11%
More stakeholder involvement
6%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges

Click here